{
    "clinical_study": {
        "@rank": "107618", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28."
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28."
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28."
            }
        ], 
        "brief_summary": {
            "textblock": "Boost vaccinations sometimes have no effect because the body has got used to the vaccine and\n      no longer reacts to it. We are therefore investigating whether vaccinating with aerosolised\n      MVA85A (a candidate tuberculosis vaccine) followed by a boost MVA85A intradermal vaccination\n      (or vice versa) avoids this and increases the immune response to vaccination."
        }, 
        "brief_title": "Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following criteria to enter the trial:\n\n          -  Healthy adult aged 18-55 years\n\n          -  Resident in or near Oxford for the duration of the trial period\n\n          -  No relevant findings in medical history or on physical examination\n\n          -  Confirmation of prior vaccination with BCG not less than 6 months prior to projected\n             trial vaccination date (by visible BCG scar on examination or written documentation)\n\n          -  Allow the Investigators to discuss the individual's medical history with their GP\n\n          -  Use effective contraception for the duration of the trial period (females only)\n\n          -  Refrain from blood donation during the trial\n\n          -  Give written informed consent\n\n          -  Allow the Investigator to register subject details with a confidential database to\n             prevent concurrent entry into clinical trials\n\n          -  Able and willing (in the Investigator's opinion) to comply with all the trial\n             requirements\n\n        Exclusion Criteria:\n\n        Subjects must meet none of the following criteria to enter the trial:\n\n          -  Any respiratory disease, including asthma\n\n          -  Current smoker\n\n          -  Clinically significant abnormality on screening chest x-ray\n\n          -  Clinically significant abnormality of pulmonary function tests\n\n          -  Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy\n\n          -  Current use of any medication taken through the nasal or inhaled route including\n             cocaine or other recreational drugs\n\n          -  Laboratory evidence at screening of latent M. tb infection as indicated by a positive\n             ELISPOT response to ESAT6 or CFP10 antigens\n\n          -  Clinical, radiological, or laboratory evidence of current active TB disease\n\n          -  Previous vaccination with candidate vaccine MVA85A or candidate vaccine FP85A or any\n             other recombinant MVA vaccine\n\n          -  Clinically significant history of skin disorder, allergy, immunodeficiency (including\n             HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease,\n             liver disease, renal disease, endocrine disorder, neurological illness, psychiatric\n             disorder, drug or alcohol abuse\n\n          -  History of serious psychiatric condition\n\n          -  Concurrent oral or systemic steroid medication or the concurrent use of other\n             immunosuppressive agents\n\n          -  History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any\n             component of the trial vaccine, sedative drugs, or any local or general anaesthetic\n             agents\n\n          -  Any abnormality of screening blood or urine tests that is deemed to be clinically\n             significant or that may compromise the safety of the subject in the trial\n\n          -  Positive HBsAg, HCV or HIV antibodies\n\n          -  Female currently lactating, confirmed pregnancy or intention to become pregnant\n             during trial period\n\n          -  Use of an investigational medicinal product or non-registered drug, live vaccine, or\n             medical device other than the trial vaccine for 30 days prior to dosing with the\n             trial vaccine, or planned use during the trial period\n\n          -  Administration of immunoglobulins and/or any blood products within the three months\n             preceding the planned trial vaccination date\n\n          -  Any other significant disease, disorder, or finding, which, in the opinion of the\n             Investigator, may either put the subject at risk or may influence the result of the\n             trial or may affect the subject's ability to participate in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954563", 
            "org_study_id": "TB035"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2", 
                "Group 3"
            ], 
            "description": "Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.", 
            "intervention_name": "MVA85A", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tuberculosis", 
            "Vaccine", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "October 8, 2013", 
        "link": {
            "description": "Jenner Institute Clinical Trials", 
            "url": "http://www.jenner.ac.uk/clinicaltrials"
        }, 
        "location": {
            "contact": {
                "email": "vaccinetrials@well.ox.ac.uk", 
                "last_name": "Zita-Rose Manjaly Thomas", 
                "phone": "01865 857406"
            }, 
            "facility": {
                "address": {
                    "city": "Oxford", 
                    "country": "United Kingdom", 
                    "state": "Oxfordshire", 
                    "zip": "OX3 7LE"
                }, 
                "name": "Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Trial Evaluating Mucosal Administration of a Candidate TB Vaccine, MVA85A, as a Way to Induce Potent Local Cellular Immune Responses and Avoid Anti-vector Immunity", 
        "overall_contact": {
            "email": "vaccinetrials@well.ox.ac.uk", 
            "last_name": "Zita-Rose Manjaly Thomas", 
            "phone": "01865 857406"
        }, 
        "overall_official": {
            "affiliation": "University of Oxford", 
            "last_name": "Helen McShane", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Actively and passively collected data on adverse events", 
            "measure": "Safety of 5 x 10^7 pfu dose of MVA85A administered by aerosol and compared to the same dose administered intradermally", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks from enrolment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Characterise mucosal and systemic immunogenicity of viral vector (MVA) and insert (Ag85A) by comprehensive characterisation of humoral and cellular immune responses\nEvaluate functional relevance of anti-vector immunity induced by aerosol and systemic immunisation in MVA85A-prime followed by homologous MVA85A-boost administered 4 weeks later", 
            "measure": "Immunogenicity of 5 x 10^7 pfu dose of MVA85A administered by aerosol followed by the same dose administered intradermally, compared to the same dose of MVA85A given intradermally and boosted by aerosol", 
            "safety_issue": "No", 
            "time_frame": "24 weeks from enrolment"
        }, 
        "source": "University of Oxford", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Oxford", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}